EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database

Yuqin Yang, Yaping Huang, Yifan Wang, Yan Chen, Chengjie Ke, Maohua Chen

Frontiers in Oncology · 10.06.2026 · 16

DOI: 10.3389/fonc.2026.1694602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 10.06.2026. Verfasst von Yuqin Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second People's Hospital, Wuhu, Anhui, China. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Romidepsin is a class I-selective histone deacetylase (HDAC) inhibitor indicated for the treatment of adult patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy and for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Despite its clinical use, large-scale safety data remain limited. This study leverages the FDA Adverse Event Reporting System (FAERS) database to characterize romidepsin-associated adverse events (AEs) in real-world settings, aiming to enhance clinical risk management.

Methods

Data from the FAERS database, spanning from January 2014 to March 2025, served as the basis for this analysis. To evaluate the association between romidepsin and AEs, multiple disproportionality analyses were employed, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS).

Results

Within the specified reporting period, 17,448,626 AE reports were recorded in the FAERS database, of which 1,285 events were associated with romidepsin. Based on four calculation methods, 101 preferred terms (PTs) related to romidepsin were determined. Common AEs included thrombocytopenia, pyrexia, anemia, electrocardiogram QT prolonged, and infections, aligning with the drug label. In addition, some unanticipated major AEs were detected, including cardiotoxicities beyond QT prolongation (acute cardiac failure, atrial fibrillation, sinus tachycardia, mitral valve incompetence, and bundle branch block left) alongside other significant AEs: hepatic failure, amenorrhea, mental status changes, glomerular filtration rate decreased, embolism, and retinal detachment.

Conclusion

This study provides a systematic evaluation of AEs associated with romidepsin, confirming its established safety profile and identifying several emerging safety concerns in a real-world setting. These findings offer valuable insights to assist clinicians and pharmacists in better-managing romidepsin’s safety.

Schlagwörter

Stichwörter der Autor:innen

FAERScutaneous T-cell lymphomasperipheral T-cell lymphomaspharmacovigilance studyromidepsin

Autor:innen und Institutionen

  • Department of Pharmacy, The Second People's Hospital, Wuhu, Anhui, China.
  • Department of Pharmacy, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
  • College of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Pingtan Comprehensive Experimental Area, Fuzhou, China.
  • Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Zitieren

APA

Yang, Y., Huang, Y., Wang, Y., Chen, Y., Ke, C., & Chen, M. (2026). A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1694602

Vancouver

Yang Y, Huang Y, Wang Y, Chen Y, Ke C, Chen M. A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1694602

BibTeX
@article{Yang2026,
  author = {Yang, Yuqin and Huang, Yaping and Wang, Yifan and Chen, Yan and Ke, Chengjie and Chen, Maohua},
  title = {A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1694602}
}
Kostenlos starten →